Journal
CELL REPORTS
Volume 17, Issue 2, Pages 366-373Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2016.09.022
Keywords
-
Categories
Funding
- National Cancer Institute of the NIH [5RO1CA172023, 5RO1CA190477, 5RO1CA085533, RO1GM105933, RO1GM115961]
Ask authors/readers for more resources
Although previous studies indicate that loss of p53-mediated cell cycle arrest, apoptosis, and senescence does not completely abrogate its tumor suppression function, it is unclear how the remaining activities of p53 are regulated. Here, we have identified an acetylation site at lysine K98 in mouse p53 (or K101 for human p53). Whereas the loss of K98 acetylation (p53(K98R)) alone has very modest effects on p53-mediated transactivation, simultaneous mutations at all four acetylation sites (p53(4KR): K98R+ 3KR[K117R+K161R+K162R]) completely abolish its ability to regulate metabolic targets, such as TIGAR and SLC7A11. Notably, in contrast to p53(3KR), p53(4KR) is severely defective in suppressing tumor growth in mouse xenograft models. Moreover, p53(4KR) is still capable of inducing the p53-Mdm2 feedback loop, but p53-dependent ferroptotic responses are markedly abrogated. Together, these data indicate the critical role of p53 acetylation in ferroptotic responses and its remaining tumor suppression activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available